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1 Introduction
More than 220,000 women every year are diagnosed with breast cancer, making it the second leading cause
of cancer death in women [1]. Most of these deaths are caused by cancer that has spread to other parts of
the body. Indeed, 30% of women who are diagnosed while in the early stages of breast cancer will have the
cancer recur or have metastatic disease. Furthermore, greater than 70% of patients diagnosed have invasive
tumors [2].
In fighting this disease, many approaches have been used to try to understand and specifically target breast
cancer. One technique that has been particularly powerful for gaining a better perspective of the underlying
mechanisms driving disease has been microarray technologies. Microarray data show expression levels of
genes within a population of cells at a specific time point. This data is analyzed quantitatively and statistically
to find abnormal levels of genes which can be caused by misregulation of cancerous cells. In some cases,
this misregulation helps drive disease progression.
One particular study has providedmicroarray data from 295 breast cancer patients in addition to extensive
clinical data such as the following: presence of metastatic tumors, tumor size, and patient survival [3, 4].
This dataset is publicly available and is the dataset used for this project.
By identifying genes that predict and correlate with clinical outcomes, and particularly individual genes
in specific pathways displaying coordinated behavior, we hope to identify novel therapeutic candidate targets.
2 Data
Themicroarray and clinical data for this project was downloaded from http://changlab.stanford.edu/
2005-PNAS-Data.html. From this url, two files were used. NKI_Expression_data_complete.txt
contains the microarray expression data (log10 format) and Clinical_Data_Supplement.xls contains
the clinical data for the 295 patients that participated in the study.
2.1 Microarray data preparation
As always, the data needed to be prepared for further analysis. Duplicate columns in the middle of the mi-
croarray data set were removed. These were probably left over from copy-and-pasting when the original file
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was made. Contig barcodes were mapped to Genbank EST accession numbers using the file
ArrayNomenclature_contig_accession.xls from http://bioinformatics.nki.nl/data/van-t-
Veer_Nature_2002/. Finally, the name of the columns were changed by concatenating the gene name (if
available) with its systemic name (e.g. Genbank accession number). Because multiple probes can map to
the same gene, this gives each column a unique name. Alternatively, each duplicate gene column could be
combined into a single aggregate column of expression levels. However, this was not done for this analysis.
Since our analysis is based on [5], all expression levels were converted to z-scores.
2.2 Adding gene names using BLAST
The original data is from 2005. Many of the probes do not have a gene name associated with them (11,121
probes). Since most pathway analysis tools use gene names rather than Genbank accession numbers, it was
decided to run the accession numbers with no gene name through BLAST to see if any more gene names
could be added. A standalone version of BLAST (version 2.2.30+) was used along with a copy of the rna
sequence files. blastn was performed on accession numbers in the dataset that did not have a gene name
associated with it.
At the command line, the following command was used for each of the query files (query files contain
accession numbers to align):
blastn -query NoName_query01.txt -db refseq_rna -out NoName_output01.txt -outfmt "6 qacc
sacc sscinames stitle pident evalue"
Since BLAST returns multiple sequence alignments for most queries, the alignment with the lowest e-
value was chosen (e-value is a kind of p-value that also takes into account sequence length and is calculated
by the BLAST software). If multiple alignments have the same e-value, the one with the highest coverage
was chosen.
After adding the BLAST results, probes with gene names increased from 13,360 to 18,919. However,
5562 still have no gene name.
2.3 Caching p-values
For our initial analysis, many p-values needed to be calculated. Since there are 24,481 probes, it was decided
to cache the results in order to save computing time.
On looking at the data, it seemed reasonable to truncate the fraction of patients in the high expression
group between 0.1 and 0.9 to make the log-rank test valid (see Figure 3). This means that at 0.1, about 30
patients will be in the high expression group, while at 0.9, about 30 patients will be in the low expression.
Between 0.1 and 0.9, 100 log-rank tests were performed for each gene. This translates to 100 p-values per
gene.
2.4 Software for analysis
The Python programming language was used for data preparation and analysis. Major packages used were
Pandas (a package for easily manipulating tabular data) and lifelines (used for Kaplan-Meier curves and
log-rank testing). Jupyter (formerly known as IPython) was used as the programming environment.
Preliminary pathway analysis was done using the Reactome database (reactome.org).
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3 Analysis and results
Briefly, we want to use the microarray data and clinical data to find significant genes present in breast cancer.
We can combine the microarray data and clinical data by doing multiple log-rank tests to find significant p-
values. These p-values are used to rank genes. By changing three variables (a p-value threshold, minimum
number of “hits”, and consecutive hits), we can produce lists of genes that can be run through pathway
analysis software. The results of the pathway analysis can show what pathways are affected by the genes in
the lists produced, which in turn could lead to new drug targets.
3.1 Background
The initial idea for analyzing the microarray data in the way described later in this article came from [5].
In this paper, they presented a survival curve like Figure 1, which showed the percentage of patients that
lived metastasis free. The patients were divided into two groups, depending on whether they expressed
higher or lower amounts of FAK1. In this particular paper, two-thirds were in the high expression group.
The distribution of z-scores is presented in Figure 2 and shows where the patients were partitioned for the
Kaplan-Meier curve in Figure 1.
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Figure 1: Reproducing figure from [5] showing the survival curve for FAK1 (or PTK2). P-value was
calculated using the log-rank test.
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Figure 2: From [5] showing the distribution of z-scores across 295 patient samples. Data sorted by z-score.
3.2 Plotting multiple p-values
It seemed that partitioning the patients at 2/3 was somewhat arbitrary. To see how p-value varied with the
partition location, it was decided to start with 10% (or about 30) of the patients in the high expression group
and incrementally add patients to the high expression group until 90% of the patients were in the high ex-
pression group. A log-rank test was performed after every transfer. Figure 3 shows how p-value changes
as more samples are shifted to the high expression group. Figure 4 is the same as Figure 3 except that the
maximum value on the y-axis has been lowered to 0.05. Keep in mind that each point in these two plots is
the p-value of a single log-rank test and that the partition between groups moved so that one group gains
about 2 patients and the other loses 2 patients.
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Figure 3: Plots how the p-value from log-rank tests varies with the partitioning of high and low expression
groups. Red line indicates a p-value of 0.05.
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Figure 4: Same as Figure 3, but with the upper limit of the y-axis lowered from 1 to 0.05. The black, dashed
line indicates a p-value of 0.005.
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Referring to Figure 3, a common trend was that the p-values at the ends would rise sharply. A possible
explanation is not having enough patients in one of the groups. This is the reason the analysis was restricted
to looking at p-values where the fraction of patients in the high expression group varied between 0.1 and 0.9.
Although the high p-values occurred in many of the genes, some genes did not show this behavior. A
possible reason is that some patients express very high levels or very low levels of a gene (see Figure 2).
This causes one of the groups to be unfairly weighted and the log-rank test to conclude that the two groups
are significant, even though only a few patients are in one of the groups.
Another hypothesis is that these extreme patients are in fact a subgroup of the total data. One could
possibly define a set partition at some value like 0.7 and see whether certain genes have similar numbers of
hits. However, enough patients need to be in the groups to give statistically valid results.
Focusing on the middle portion of Figure 3, there is a region of low p-values. The length of this region
could indicate how robust the partition is in that region. For example, if the region were only two or three
points, one could transfer 4 or 5 patients and the two groups would not be significant. Defining stability as
the number of consecutive hits will be used later as one of two ways to create gene lists.
3.3 Using p-values as a ranking criterion
As seen from Figure 4, depending on where the partition between high and low expression is set, the p-value
will change. In order to use these p-values as ranking criteria, the p-values needed to be aggregated. There
are many possible ways to do this, but we decided to do two things: First, set a p-value threshold. Because
lower p-values are understood to be more significant, log-rank tests with p-values less than or equal to this
threshold are labeled as a hit. Second, we count the number of hits for each gene. In this way, genes with
more hits are assumed to be more significant. Therefore, the number of hits can be used to rank genes.
Figure 5 shows how the number of significant genes vary with p-value threshold and minimum number
of hits. The most important conclusion is that the number of genes is affected more by the p-value threshold
than by the minimum number of hits.
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Figure 5: A plot of the number of genes that have at least a certain number of hits below the p-value
threshold. Maximum possible hits is 100.
6
Another way to generate gene lists was hinted in the previous section. Most genes have places on the
p-value plots where the p-value stays very low over an extended region (Figure 3). This can be used as
measure of how robust that gene is and can be used to generate different gene lists. Figure 6 shows how the
number of genes varies with p-value, but this time as a function of how wide the stable region is, which is
the number of consecutive hits below the p-value threshold. As in Figure 5, the number of genes is more
strongly affected by p-value threshold. Also, using consecutive hits, the number of genes drops more rapidly
as the minimum number of consecutive hits is increase.
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Figure 6: Illustrates how the number of valid genes varies with p-value threshold and consecutive hits.
Maximum possible hits is 100.
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3.4 Creating gene lists
To feed into pathway analysis tools, gene lists needed to be generated. As a first pass, the parameters were
solely based on having a gene list of manageable size, but still contain as many genes as possible. Based on
Figure 5, a p-value threshold of 0.005 and a minimum number of hits of 20 were chosen. The distribution of
the list generated is shown in Figure 7. Table 1 shows the top ten hits for the p-value threshold of 0.005 and
minimum hits of 20. After removing duplicate gene names, the total number of genes in the list was 2138.
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Figure 7: Showing the number of hits for each gene. Maximum number of hits is 100. Duplicate gene
names were removed. Total number of genes is 2138.
Table 1: The first 10 genes with a p-value threshold of 0.005 and minimum of 20 hits.
gene_name hits
BIRC5 100
ARHI 98
DKFZP586E1519 98
UBCH10 97
DKFZp762E1312 97
PRC1 96
AW137640 96
STK15 96
SESN3 96
KIAA0165 96
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A second gene list using consecutive hits was also generated. The distribution of hits is plotted in Figure
8 and the top 10 hits are shown in Table 2. The total number of genes with consecutive hits of at least 20 was
1528 (after removing duplicate gene names).
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Figure 8: The distribution of hits using consecutive hits.
Table 2: The first 10 genes using a p-value threshold of 0.005 and consecutive hits of at least 20
gene_name hits
DKFZP586E1519 98
ARHI 98
DKFZp762E1312 97
UBCH10 97
PRC1 96
SESN3 96
AW137640 96
KIAA0165 96
STK15 96
PSMD7 95
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3.5 Preliminary pathway analysis
Table 3 shows the first 10 pathways for minimum number hits of 20 and p-value of 0.005 using reactome.
org. The results are sorted by p-value for that pathway. In total, 1257 pathways were identified using this
gene list. Unfortunately, 1338 gene names in the list were not found in the database. This means about 62.6%
of the genes in the list were not included in the pathway analysis.
Table 3: Top ten pathway results for minimum hits of 20. Duplicate gene names were removed before
submitting to Reactome.org.
Pathway name # Entities found Entities pValue Entities FDR
Nonsense Mediated Decay (NMD) independent of t... 41 0.000143 0.105741
Peptide chain elongation 40 0.000183 0.105741
Eukaryotic Translation Termination 39 0.000434 0.124386
Eukaryotic Translation Elongation 40 0.000504 0.124386
Formation of a pool of free 40S subunits 38 0.001667 0.267658
Nonsense-Mediated Decay (NMD) 43 0.001705 0.267658
Nonsense Mediated Decay (NMD) enhanced by the ... 43 0.001705 0.267658
G1/S-Specific Transcription 11 0.002328 0.305014
SRP-dependent cotranslational protein targetin... 42 0.002480 0.305014
G2/M Checkpoints 23 0.003476 0.386538
For the gene list with consecutive hits of 20 and p-value of 0.005, the top 10 pathways are presented in
Table 4. Total number of pathways identified was 1127. As with the minimum hits gene list, about 943 genes
were not found in the pathway database. This means that about 61.7% of the gene names were not used in
the pathway analysis.
Table 4: Top ten pathway results for consecutive hits of 20. Duplicate gene names were removed before
submitting to Reactome.org.
Pathway name # Entities found Entities pValue Entities FDR
Nonsense Mediated Decay (NMD) independent of t... 33 0.000072 0.038668
Peptide chain elongation 32 0.000109 0.038668
Eukaryotic Translation Termination 32 0.000132 0.038668
Eukaryotic Translation Elongation 32 0.000271 0.056625
Cell Cycle, Mitotic 113 0.000357 0.058220
Cell Cycle Checkpoints 38 0.000477 0.058220
Nonsense-Mediated Decay (NMD) 35 0.000509 0.058220
Nonsense Mediated Decay (NMD) enhanced by the ... 35 0.000509 0.058220
Polo-like kinase mediated events 12 0.000540 0.058220
Formation of a pool of free 40S subunits 31 0.000560 0.058220
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4 Discussion
4.1 Improving BLAST results
The first improvement is completelymapping accession numbers to gene names. As stated in the data section,
5562 probes do not have an associated gene name. It turns out that there were problems while doing the
BLAST search. Apparently, BLAST can only handle about 500 accession numbers at once. This may be
limited by the memory capacity on the computer used. The end result was that not all accessions sent to
BLAST were actually submitted to BLAST.
4.2 Cutoffs for making gene lists
For this project, the p-value threshold, minimum hits, and minimum consecutive hits were set somewhat
arbitrarily. The p-value threshold of 0.005 was set based solely on keeping the gene list to a manageable
size. Now that the first run has been completed, this p-value threshold will be set more appropriately. We
can look at p-value profile for genes that are already known to play important roles in breast cancer. For
instance, FAK is known to have a significant impact [6]. Looking at Figure 4, we already see that we should
probably change the threshold to at least 0.01 in order to include FAK.
The minimum number of hits is not as important as setting the p-value threshold because the number of
genes is affected more by the p-value threshold (see Figure 5). The same trend holds for consecutive hits.
The minimum number of hits and consecutive hits parameters will likely be set based on studying the results
from pathway analysis, since these parameters affect the genes that are at the bottom of the generated list of
relevant pathways. Also, there is a bug in the filter used to for consecutive hits. If you compare Table 1 with
Table 2, BIRC5 should also be in Table 2. However, this does not affect the results very much because that
is the only gene missing from Table 2.
4.3 Preliminary pathway analysis
From Tables 3 and 4, the top results for both gene lists are more or less the same. But it is interesting that the
p-values are lower for the consecutive hit list. This could possibly happen because the gene list for minimum
hits is larger (800 gene names) than the gene list for consecutive hits (585 gene names). However, the p-value
could also be lowered because the consecutive hits list is more specific, making the pathways found more
significant.
In contrast to the top of both pathway lists, the list of pathways become increasingly diverse. As men-
tioned in the previous subsection, the minimum hits or consecutive hits limits will affect these more diverse
pathways. More pathway analysis and possible mRNA knockdown experiments will be needed to verify a
relevant limit.
As stated earlier, approximately 60% of the gene names in both lists were not found in the Reactome
database. This is partially due to not having complete BLAST results. Even after correcting the BLAST
problem, a few gene names will still not be filled because some “accession numbers” are actually antibody
barcodes. However, on looking at the list of gene names not found, many are actual gene names. A possible
explanation is that the Reactome database is not large enough. Further analysis with other pathway analy-
sis tools, such as Ingenuity Pathway Analysis (IPA, http://www.ingenuity.com/products/ipa), may
ameliorate this problem.
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5 Conclusion
By performing log-rank tests, we were able to develop a unique ranking criterion based on the p-values for
multiple partitions of the 295 patients. Using this criterion, we ranked genes. We also developed a measure
of stable regions of p-values by looking at the number of consecutive hits. Using these parameters (p-value
threshold, minimum consecutive hits, or minimum hits), we created lists of genes that are possibly significant
with respect to metastasis-free survival. These gene lists were run through the Reactome pathway database
and some preliminary analysis was done. In addition, we also have ideas for extending our work such as
doing more pathway analysis, RNA knockdown experiments, and using other clinical data included in the
dataset. We hope that the process of creating these gene lists and subsequent pathway analysis will lead us
to new drug targets and to new pathways to target in the fight against breast cancer.
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